B-type natriuretic peptide (BNP) is a useful prognostic biomarker in patients with reduced LVEF, but data in heart failure (HF) with preserved ejection fraction (HFPEF) is minimal
A recent study sought to determine the prognostic value of BNP in patients with HFPEF in comparison to data in HF patients with reduced left ventricular EF <40%
615 patients with mild to moderate HF were followed for 18 months and BNP was measured at baseline and related to the primary outcomes (mortality and HF hospitalization)
BNP levels were significantly higher in patients with reduced LVEF than in those with HFPEF (p < 0.001), however the risk of adverse outcomes and prognosis in patients with HFPEF is as poor as in those with reduced LVEF
References
B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction. Veldhuisen D, Linssen G, et al. J Am Coll Cardiol 2013; 61:1498-506
